Results 161 to 170 of about 6,540 (205)

Effect of lovastatin on hemorheology in type II hyperlipoproteinemia

Atherosclerosis, 1990
To assess the effect of lovastatin on blood rheology, the hemorheological determinants fibrinogen, red cell aggregation, plasma viscosity, hematocrit and platelet aggregation (spontaneous and ADP-induced) were studied in 15 patients with type II hyperlipoproteinemia in the course of treatment with lovastatin.
R, Koppensteiner, E, Minar, H, Ehringer
openaire   +2 more sources

Hypertrophy of liver peroxisomes in type II and type IV hyperlipoproteinemia

Atherosclerosis, 1986
A morphometric study on liver biopsies from patients with primary hyperlipoproteinemia (IIa n = 4, IIb n = 7, IV n = 7) and in controls (n = 7) was performed by light and electron microscopy. We found hypertrophy of peroxisomes in all subjects with hyperlipoproteinemia.
P, Gariot, B, Foliguet, P, Drouin, E, Barrat, P, Genton, G, Debry   +5 more
openaire   +2 more sources

Colestipol in familial type II hyperlipoproteinemia: A three‐year trial

Clinical Pharmacology & Therapeutics, 1976
Colestipol. a new bile acid sequestrant polymer. has been shown to lower the serum cholesterol level more than 30% in 13 patients with familial type 11 hyperlipoproteinemia. Placebo for 6 wk was followed by colestipol for periods up to 36 mo. A slight but not significant increase of serum triglyceride concentrations was observed during the first 18 mo.
C, Harvengt, J P, Desager
openaire   +2 more sources

Elevated levels of sphingolipids in type II (a+b) hyperlipoproteinemia

Thrombosis Research, 1974
Abstract The levels of sphingomyelin, neutral glycosphingolipids and gangliosides were studied in normal and type II hyperproteinemic plasmas. Sphingomyelin levels were elevated and there was an excellent correlation between cholesterol and sphingomyelin (r=0.86). The correlation between cholesterol and the remainder of the phospholipids (i.e., total
T B, Auran, J H, Zavoral, W, Krivit
openaire   +2 more sources

Pediatric Familial Type II Hyperlipoproteinemia: Therapy With Diet and Colestipol Resin

Pediatrics, 1976
Effects of a low-cholesterol, polyunsaturate rich diet and a synthetic organic bile sequestrant polymer (U26,597A, colestipol) were studied in 21 children, heterozygous for familial hypercholesterolemia. Total cholesterol, β-lipoprotein cholesterol, and triglyceride were measured twice on habitual diet, monthly for six months on a low-cholesterol diet,
C J, Glueck, R W, Fallat, M, Mellies, R C, Tsang   +3 more
openaire   +2 more sources

[Familial IgM deficiency and type II hyperlipoproteinemia].

Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1978
It is reported on the common appearance of a hyperlipoproteinaemia type II after Fredrickson and of a selective insufficiency of IgM in a family. The two generations of a family which have been observed since three years show these disturbances in a 42-year-old patient and all his four children.
H, Storch, B, Kuklinski, H, Schwenke
openaire   +1 more source

Coronary Artery Disease Risk in Familial Type II Hyperlipoproteinemia

1974
Prospective and retrospective analyses of coronary artery disease (CAD) risk for affected and non-affected members of kindred with familial hypercholesterolemia, (Type II hyperlipoproteinemia), vary considerably. Slack found that by age 60, the risk of CAD and CAD death in first degree male relatives of Type II propositi was 85.4% and 54.1 ...
Neil J. Stone, Robert I. Levy, Donald S. Fredrickson, Joel Verter   +3 more
openaire   +1 more source

Cholestyramine in Type II Hyperlipoproteinemia

Annals of Internal Medicine, 1973
R I, Levy, D S, Fredrickson, N J, Stone, D W, Bilheimer, W V, Brown, C J, Glueck, A M, Gotto, P N, Herbert, P O, Kwiterovich, T, Langer, J, LaRosa, S E, Lux, A K, Rider, R S, Shulman, H R, Sloan   +14 more
openaire   +2 more sources

Early Diagnosis of Familial Type II Hyperlipoproteinemia

Annals of Nutrition and Metabolism, 1973
H, Greten, H, Wengeler, H, Wagner
openaire   +2 more sources

Treatment of hyperlipoproteinemia type II with etofibrate.

International journal of clinical pharmacology and biopharmacy, 1980
Seven patients with hyperlipoproteinemia (HLP) type II (four patients with type II A and three patients with type II B), who were experienced to be resistant to hypolipidemic drugs, were treated for 6 months with etofibrate, a double-ester of nicotinic acid and clofibrinic acid, at a dose of 0.3 g t.i.d.
openaire   +1 more source